Filtered By:
Condition: Heart Disease
Drug: Aspirin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 179 results found since Jan 2013.

Premature Ventricular Complexes on Screening Electrocardiogram and Risk of Ischemic Stroke Brief Reports
Conclusions— PVCs are common on routine screening ECGs and are associated with an increased risk of ischemic stroke.
Source: Stroke - April 27, 2015 Category: Neurology Authors: Agarwal, S. K., Chao, J., Peace, F., Judd, S. E., Kissela, B., Kleindorfer, D., Howard, V. J., Howard, G., Soliman, E. Z. Tags: Electrocardiology, Embolic stroke, Epidemiology Brief Reports Source Type: research

FDA strengthens warning that NSAIDs increase heart attack and stroke risk
Back in 2005, the FDA warned that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen increased the risk of having a heart attack or stroke. Last week it took the unusual step of further strengthening this warning. This was done on the advice of an expert panel that reviewed new information about NSAIDs and their risks. Because NSAIDs are widely used, it’s important to be aware of downsides of taking an NSAID and to take steps to limit the risk. Many people take NSAIDs to relieve mild to moderate pain. These medications may be particularly effective in conditions in which pain results pri...
Source: New Harvard Health Information - July 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health heart attack heart disease NSAIDS Stroke Source Type: news

CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy
This study measures effect ofCYP2C19 genotype on ischemic stroke risk during clopidogrel therapy for asymptomatic, extracranial carotid stenosis patients. Using deidentified electronic health records, patients were selected for retrospective cohort using administrative code for carotid stenosis, availability ofCYP2C19 genotype result, clopidogrel exposure, and established patient care. Patients with intracranial atherosclerosis, aneurysm, arteriovenous malformation, prior ischemic stroke, or observation time<1 month were excluded. Dual antiplatelet therapy patients were included. Patients with carotid endarterectomy or ...
Source: Translational Stroke Research - February 21, 2021 Category: Neurology Source Type: research

Use of antiplatelet drugs in stroke prevention: time for a rethink?
Worldwide, 15 million people suffer stroke each year from which a third die and a further third sustain severe disability, with ischaemic events accounting for ~80% of all strokes.1 The annual estimated economic burden of stroke is 64.1 billion in Europe alone.2 While recent major investments in acute stroke services have focused on thrombolysis and hospitalisation in dedicated stroke wards, we believe that primary and secondary stroke prevention should remain of utmost importance in a disease that carries such serious permanent neurological sequelae. Antiplatelet agents such as aspirin, diypridamole or clodpidogrel are ph...
Source: Postgraduate Medical Journal - May 17, 2013 Category: Journals (General) Authors: Loke, Y. K., White, J. R., Bettencourt-Silva, J. H., Potter, J. F., Myint, P. K. Tags: GI bleeding, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Epidemiology Editorials Source Type: research

Meta-analysis finds benefit for dual antiplatelet therapy but limitations preclude changing standard mono antiplatelet therapy approach for acute non-cardioembolic ischaemic stroke or transient ischaemic attack
Commentary on: Wong KSL, Wang Y, Leng X, et al.. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack. An updated systematic review and meta-analysis. Circulation 2013;128:1656–66. Context Current guidelines recommend aspirin, aspirin plus clopidogrel or aspirin plus extended-release dipyridamole for treatment of acute ischaemic stroke (IS) or transient ischaemic attack (TIA) to prevent recurrent stroke, myocardial infarction and cardiovascular death.1 The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial ra...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Aronow, W. S. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease Therapeutics Source Type: research

Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial Clinical Sciences
Conclusions— Unexpected interactions between assigned antiplatelet therapy and each of ischemic heart disease and normal/prehypertensive status accounted for increased mortality among patients with recent lacunar stroke given dual antiplatelet therapy. Despite extensive exploratory analyses, the mechanisms underlying these interactions are uncertain. Clinical Trial Registration— URL: http://www.SPS3ClinicalTrials.gov. Unique identifier: NCT00059306.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Sharma, M., Pearce, L. A., Benavente, O. R., Anderson, D. C., Connolly, S. J., Palacio, S., Coffey, C. S., Hart, R. G. Tags: Cerebral Lacunes, Antiplatelets Clinical Sciences Source Type: research

Platelet Count Predicts Adverse Clinical Outcomes After Ischemic Stroke or TIA: Subgroup Analysis of CNSR II
Conclusion: In ischemic stroke or TIA patients with platelet count within normal range, platelet count may be a qualified predictor for long-term recurrent stroke, mortality, and poor functional outcome. Introduction Platelets exert a critical role in the pathogenesis of atherosclerotic complications of cardio-cerebrovascular disease, contributing to thrombus formation, and embolism (1, 2). Previous literature reported that platelets of various size and density are produced by megakaryocytes of different size and stages of maturation in different clinical conditions, suggesting various platelet patterns in differen...
Source: Frontiers in Neurology - April 11, 2019 Category: Neurology Source Type: research

Stroke-Related Disease Comorbidity and Secondary Stroke Prevention Practices Among Young Stroke Survivors
Conclusions: Many young stroke survivors exhibit comorbid disease conditions that are similar to older stroke survivors. A large percentage are engaged in general chronic disease and secondary stroke prevention practices, yet less than two-thirds had seen a general doctor in the past 12 months. Primary care doctors and other health professionals are critical to the implementation of disease management strategies that consider their age, secondary stroke risk, expected life spans, and other issues that differ from older adult stroke survivors.
Source: Journal of Neuroscience Nursing - September 8, 2017 Category: Neuroscience Tags: Article Source Type: research

Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report.
We report the case of an elderly patient with permanent AF and coronary heart disease, who had already suffered an ischemic stroke while on warfarin treatment, and was consequently switched to treatment with an association of Rivaroxaban and Aspirin. Her CHA2DS2-VASc score was 9. The patient developed a severe recurrent disabling ischemic stroke. This case goes to show that the novel direct anticoagulants may fail to prevent recurrent stroke in patients at particularly high risk, even when associated with antiplatelet drugs. PMID: 27228488 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - May 27, 2016 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Vital signs: avoidable deaths from heart disease, stroke, and hypertensive disease - United States, 2001-2010.
Conclusions: Nearly one fourth of all cardiovascular disease deaths are avoidable. These deaths disproportionately occurred among non-Hispanic blacks and residents of the South. Persons aged <65 years had lower rates than those aged 65-74 years but still accounted for a considerable share of avoidable deaths and demonstrated less improvement. Implications for Public Health Practice: National, state, and local initiatives aimed at improving health-care systems and supporting healthy behaviors are essential to reducing avoidable heart disease, stroke, and hypertensive disease deaths. Strategies include promoting the ABCS ...
Source: MMWR Morb Mortal Wkl... - September 6, 2013 Category: Epidemiology Authors: Centers for Disease Control and Prevention (CDC) Tags: MMWR Morb Mortal Wkly Rep Source Type: research

A pilot study of the ticagrelor role in ischemic stroke secondary prevention
Conclusion: Ticagrelor was noninferior to aspirin regarding safety profile. Compared with aspirin, ticagrelor had a better clinical outcome based on NIHSS and mRS in first-ever acute ischemic stroke patients who received it within 9 h from symptom onset, leading to a shorter hospital stay.Eur Neurol
Source: European Neurology - August 30, 2021 Category: Neurology Source Type: research

The Effect of Tobacco Control Measures during a Period of Rising Cardiovascular Disease Risk in India: A Mathematical Model of Myocardial Infarction and Stroke
Conclusions Smoke-free laws and substantially increased tobacco taxation appear to be markedly potent population measures to avert future cardiovascular deaths in India. Despite the rise in co-morbid cardiovascular disease risk factors like hyperlipidemia and hypertension in low- and middle-income countries, tobacco control is likely to remain a highly effective strategy to reduce cardiovascular deaths.Please see later in the article for the Editors' Summary
Source: PLoS Medicine - July 9, 2013 Category: Internal Medicine Authors: Sanjay Basu et al. Source Type: research

Here ’s Why Aspirin Is Important for Preventing Heart Disease
By now, it’s not a surprise that doctors advise anyone who has had a heart attack or stroke to take a low-dose aspirin every day. But remembering to take a pill daily can be a challenge. In a new study published Monday in the journal Circulation, researchers show just how risky stopping aspirin therapy can be. They followed more than 601,000 people who took low-dose aspirin (80mg) daily to prevent heart disease and stroke. Three years after the study began, people who stopped taking aspirin for whatever reason had a 37% higher rate of heart problems including heart attack and stroke, compared to those who continued r...
Source: TIME.com: Top Science and Health Stories - September 25, 2017 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized aspirin aspirin and heart disease onetime Stroke Source Type: news

Why It ’s So Risky for Heart Patients to Stop Taking a Daily Aspirin
By now, it’s not a surprise that doctors advise anyone who has had a heart attack or stroke to take a low-dose aspirin every day. But remembering to take a pill daily can be a challenge. In a new study published Monday in the journal Circulation, researchers show just how risky stopping aspirin therapy can be. They followed more than 601,000 people who took low-dose aspirin (80mg) daily to prevent heart disease and stroke. Three years after the study began, people who stopped taking aspirin for whatever reason had a 37% higher rate of heart problems including heart attack and stroke, compared to those who continued r...
Source: TIME.com: Top Science and Health Stories - September 25, 2017 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized aspirin aspirin and heart disease onetime Stroke Source Type: news

Therapeutic Challenges in Patients With Noncardioembolic Acute Ischemic Stroke in Need of Double Antiplatelet Therapy for Coronary Artery Disease
Conclusions: In the acute phase of an IS, maintenance or initiation of DAPT therapy imposed by CHD relies, on one hand, on the risk of hemorrhagic transformation of the brain injury and, on the other hand, on the risk of stent thrombosis in the coronary arteries. The management of these patients must be carried on by a vascular team, on an individualized basis.
Source: American Journal of Therapeutics - March 1, 2019 Category: Drugs & Pharmacology Tags: Systematic Reviews Source Type: research